Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer

A Kenneth MacLeod¹, Lourdes Acosta-Jimenez¹, Philip J Coates¹,4, Michael McMahon¹, Frank A Carey², Tadashi Honda³, John D Hayes¹, Colin J Henderson¹ and C Roland Wolf¹

¹Division of Cancer Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK; ²Department of Pathology and Neuroscience, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK and ³Department of Chemistry and Institute of Chemical Biology and Drug Discovery, Stony Brook University, New York, NY 11794-3400, USA

Correction to: British Journal of Cancer (2016) 115, 1530–1539. doi:10.1038/bjc.2016.363; published online 8 November 2016

After publication of the above paper in the British Journal of Cancer, the authors recognised that John D Hayes had been omitted from the original author list. The authors would like to apologise for this mistake. The revised author list and affiliations appear above.